Insilico's fibrosis drug tied to 3-year drop in biological age

A small trial of an experimental fibrosis drug produced a striking side effect: patients' predicted biological age fell by roughly three years on average, and by up to six years on one measure. The data, released Sept. 7 by AI drug discovery startup Insilico Medicine, is early evidence that aging itself might be a treatable target, not just the diseases that come with it.

Feng Ren, Insilico's co-CEO and head of drug research and development, put it directly: "We might have a chance to stop biological aging." Investors took note, sending shares up 11% since the announcement. The claim is bold, but it lands at a moment when healthcare leaders are openly wrestling with the cost of a much longer-lived population.

At the Fortune Leaders Forum in Macau on Sept. 8, executives predicted children born today could see average life expectancy pass 100 within a generation. The bigger problem, they said, is paying for it. "The question is not the availability of all these new technologies. It's how we're going to make good medical care accessible to millions, and how we're going to make it affordable as we age," said Kelvin Loh, group chief healthcare officer at insurer AIA.

The math is stark. One in four people in Asia-Pacific will be over 60 by 2050, up from around one in seven now. That shift will pile more chronic conditions onto already strained healthcare systems. No wonder drugmakers are betting on a different approach: slow the underlying aging process, and the costly diseases that accompany it may arrive later, or not at all.

Loh, for his part, is more measured about the ultimate goal. "I'm very sure that we will extend life. We may not cure aging, but we are going to extend life. That is for sure," he said. He pointed to how far medicine has already come: "Cancer is no more a death sentence." Stage 4 lung cancer patients once given six months to live "can live for 10 years or more. It's becoming [a] chronic disease."

Several speakers zeroed in on "healthspan," the length of time people spend in good health, as the next target for the sector. "It's important that we don't live longer; we live healthier," said Keith Choy, president of Asia-Pacific at consumer health company Haleon. He noted that people spend roughly the last decade of their lives in poor health or with some kind of disability. That is a decade of lost productivity, higher care costs, and diminished quality of life.

Choy suggested the near future could look radically different. "Could you imagine after five or 10 years, or even shorter, maybe everyone...in China's 1.4 billion population, they can have a personal doctor." Wearable health technology and AI, he argued, could shift healthcare from reactive treatment to continuous, personalized prevention. Insilico's data, while early, offers a glimpse of that same trajectory: AI not just diagnosing disease, but designing drugs that target aging itself.

For executives across pharma, insurance, and consumer health, the implications are significant. If biological age can be measured and moved, clinical trials may need new endpoints, insurers may need new pricing models, and the line between treatment and prevention blurs. Insilico's results are a single, early data point, but they signal where the industry is heading: a race to make aging itself a treatable condition. The winners won't just extend life; they'll reshape the economics of healthcare.